Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 75 versus HC HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 75 versus HC HYDROCORTISONE.
DEXONE 0.75 vs HC (HYDROCORTISONE)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokine production; and causes vasoconstriction and immunosuppression.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
Hydrocortisone 100-500 mg IV/IM every 2-6 hours as needed for acute adrenal insufficiency or severe inflammation. Maintenance: 20-30 mg/day PO divided every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
1.5–2.5 hours (terminal half-life). In clinical context, the biological half-life (duration of HPA suppression) is longer (8–12 hours) due to tissue binding and active metabolites.
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Renal: predominantly as conjugated metabolites and a small fraction of unchanged drug. Biliary/fecal: minor, <5%. Total renal clearance accounts for >95% of elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid